Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 30 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced the commencement of a Phase IV clinical trial for Desidustat in patients with Chronic Kidney Disease induced anemia. The trial aims to generate Real World Evidence regarding the safety and efficacy of Desidustat over a period of time. This multicentre study will enroll a significant number of CKD patients in India, including both dialysis dependent and independent individuals. The press release emphasizes the importance of Real World Data in understanding the drug's effectiveness in diverse clinical settings.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 30-Aug-2022 titled Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with Chronic Kidney Disease induced anemia

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases